KBC Group NV grew its position in shares of Eli Lilly and Co (NYSE:LLY) by 4.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 782,437 shares of the company’s stock after acquiring an additional 34,560 shares during the period. Eli Lilly and comprises 0.6% of KBC Group NV’s portfolio, making the stock its 25th largest position. KBC Group NV owned 0.07% of Eli Lilly and worth $66,931,000 at the end of the most recent quarter.
Several other large investors have also recently modified their holdings of LLY. Accredited Investors Inc. raised its stake in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after buying an additional 14 shares in the last quarter. Oakworth Capital Inc. raised its stake in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after buying an additional 20 shares in the last quarter. Sfmg LLC raised its stake in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after buying an additional 20 shares in the last quarter. Jackson Grant Investment Advisers Inc. raised its stake in Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after buying an additional 24 shares in the last quarter. Finally, YorkBridge Wealth Partners LLC raised its stake in Eli Lilly and by 0.8% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after buying an additional 24 shares in the last quarter. 76.31% of the stock is owned by hedge funds and other institutional investors.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now owns 123,084,104 shares in the company, valued at $10,856,017,972.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now owns 54,885 shares in the company, valued at approximately $4,729,989.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 251,088 shares of company stock worth $22,041,236. Corporate insiders own 0.20% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) opened at $86.98 on Friday. Eli Lilly and Co has a fifty-two week low of $74.00 and a fifty-two week high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market cap of $95,770.00, a P/E ratio of 41.42, a PEG ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. During the same quarter in the prior year, the company posted $0.88 earnings per share. The business’s revenue for the quarter was up 9.0% on a year-over-year basis. sell-side analysts forecast that Eli Lilly and Co will post 4.22 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.59%. Eli Lilly and’s dividend payout ratio is presently 99.05%.
A number of equities analysts recently issued reports on the stock. BMO Capital Markets reissued a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a research note on Thursday, September 28th. Cowen reaffirmed a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 target price (up previously from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the company’s stock. Eli Lilly and has an average rating of “Hold” and an average target price of $92.14.
ILLEGAL ACTIVITY WARNING: This article was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2018/01/14/eli-lilly-and-co-lly-shares-bought-by-kbc-group-nv-updated-updated.html.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.